World

Merck, Moderna begin late-stage study of mRNA cancer vaccine

FILE PHOTO: Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) - Merck, along with its partner Moderna, began a late-stage study to evaluate their experimental mRNA-based cancer vaccine in combination with cancer therapy Keytruda, the companies said on Wednesday.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)

The Star Festive Promo: Get 35% OFF Digital Access

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In World
Urgent: At least 1 killed, over 30 injured in shopping mall fire in NE Yemen
Fire at Yemen shopping mall kills one, injures 13, state media says
Analysis-Europe aims to rely less on US defence after Trump's Greenland push
Norway's Klaebo claims record ninth Winter Olympic title (updated)
Rubio says US does not dispute Navalny poisoning assessment by Europeans
Macron urges calm after activist's death sparks political clash
Russia's Taman port damaged by Ukrainian drone strike
Ukraine's Zelenskiy says allies to provide new energy and military aid within 10 days
Rubio visits eastern Europe to bolster ties with pro-Trump leaders
Don't get sense EU countries ready to give Ukraine date for membership, EU's Kallas says

Trending in News

Others Also Read

Load more

Copyright © 1995- Star Media Group Berhad [197101000523 (10894-D)]

Best viewed on Chrome browsers.